Search
01/03/2024
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).
01/03/2024
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).
01/03/2024
What About Variant Histologies in Bladder Cancer?
Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).
01/02/2024
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families
Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).
01/02/2024
Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.
Villarrubia, JE, Gordoa, TA, Mellado-González, B, Duran, I, Pinto, A, Sanchez, A, Pous, AF, Vazquez-Estevez, S, Puente, J, Grande, E, Climent, MA, Maroto-Rey, P, Perez-Gracia, JL, Aix, SP, Castellano, D, Gonzalez-Billalabeitia, E. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(4_SUPPL)DOI:10.1200/JCO.2024.42.4_suppl.TPS238. PMID:. IF:41.900(Q1/1D).
20/01/2024
Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.
Pacheco-Barcia, V, Méndez, AM, Carmona-Bayonas, A, Gallego, J, Franco, CF, Adeva, J, Cerdà, P, Cabezon-Gutierrez, L, Custodio-Cabello, S, Ghanem, I, Hernandez, I, Lamarca, A, Laquente, B, López-Alfonso, A, Lago, NM, Macarulla, T, Peiro, I, Visa, L, Jimenez-Fonseca, P, Muñoz, A. Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.623. PMID:. IF:41.900(Q1/1D).